계산
순이익률(Net Profit Margin Ratio) | = | 100 | × | 순이익(손실)1 | ÷ | 수익1 | |
---|---|---|---|---|---|---|---|
2023. 12. 31. | 36.68% | = | 100 | × | 3,619,600) | ÷ | 9,869,200) |
2022. 12. 31. | 37.20% | = | 100 | × | 3,322,000) | ÷ | 8,930,700) |
2021. 12. 31. | 30.92% | = | 100 | × | 2,342,100) | ÷ | 7,574,400) |
2020. 12. 31. | 43.70% | = | 100 | × | 2,711,647) | ÷ | 6,205,683) |
2019. 12. 31. | 28.27% | = | 100 | × | 1,176,810) | ÷ | 4,162,821) |
2018. 12. 31. | 68.80% | = | 100 | × | 2,096,896) | ÷ | 3,047,597) |
2017. 12. 31. | 10.59% | = | 100 | × | 263,484) | ÷ | 2,488,652) |
2016. 12. 31. | -6.58% | = | 100 | × | (112,052) | ÷ | 1,702,177) |
2015. 12. 31. | -53.89% | = | 100 | × | (556,334) | ÷ | 1,032,336) |
2014. 12. 31. | -127.25% | = | 100 | × | (738,555) | ÷ | 580,415) |
2013. 12. 31. | -36.72% | = | 100 | × | (445,028) | ÷ | 1,211,975) |
2012. 12. 31. | -7.01% | = | 100 | × | (107,032) | ÷ | 1,527,042) |
2011. 12. 31. | 2.10% | = | 100 | × | 29,574) | ÷ | 1,410,626) |
2010. 12. 31. | -526.35% | = | 100 | × | (754,626) | ÷ | 143,370) |
2009. 12. 31. | -630.27% | = | 100 | × | (642,178) | ÷ | 101,889) |
2008. 12. 31. | -262.02% | = | 100 | × | (459,851) | ÷ | 175,504) |
2007. 12. 31. | -196.61% | = | 100 | × | (391,279) | ÷ | 199,012) |
2006. 12. 31. | -95.63% | = | 100 | × | (206,891) | ÷ | 216,356) |
2005. 12. 31. | -126.43% | = | 100 | × | (203,417) | ÷ | 160,890) |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
1 US$ 단위 천
경쟁사와의 비교
Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023. 12. 31. | 36.68% | 8.95% | 24.96% | 17.83% | 19.94% | 15.36% | 21.03% | 41.28% | 0.61% | -70.66% | 3.62% | 30.14% | 13.99% |
2022. 12. 31. | 37.20% | 20.39% | 26.42% | 13.71% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 45.36% | 31.27% | 35.64% | 15.47% |
2021. 12. 31. | 30.92% | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 69.04% | 27.04% | 50.25% | 19.70% |
2020. 12. 31. | 43.70% | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | -373.77% | 22.95% | 41.35% | 19.79% |
2019. 12. 31. | 28.27% | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | — | 31.45% | 26.91% | 14.47% |
2018. 12. 31. | 68.80% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | — | 20.79% | 36.42% | 12.06% |
2017. 12. 31. | 10.59% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | — | 40.55% | 20.41% | 10.64% |
2016. 12. 31. | -6.58% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | — | 13.66% | 18.42% | 11.06% |
2015. 12. 31. | -53.89% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | — | 14.25% | 15.50% | 11.64% |
2014. 12. 31. | -127.25% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | — | 18.42% | 12.34% | 11.22% |
2013. 12. 31. | -36.72% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | — | 42.65% | 20.16% | 9.73% |
2012. 12. 31. | -7.01% | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | — | 24.70% | 54.43% | 9.42% |
2011. 12. 31. | 2.10% | — | 24.08% | 17.46% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | — | 14.84% | -49.74% | 11.34% |
2010. 12. 31. | -526.35% | — | 31.56% | 15.92% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | — | 12.18% | -22.76% | 9.60% |
2009. 12. 31. | -630.27% | — | 32.09% | 56.42% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | — | 17.27% | -17.88% | 8.41% |
2008. 12. 31. | -262.02% | — | 28.57% | 25.47% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | — | 16.78% | -34.69% | 9.47% |
2007. 12. 31. | -196.61% | — | 22.12% | 11.19% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | — | 16.82% | -84.46% | 7.81% |
2006. 12. 31. | -95.63% | — | 21.29% | 8.85% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | — | 39.98% | -161.30% | 4.46% |
2005. 12. 31. | -126.43% | — | 30.56% | 15.62% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | — | 15.76% | -144.19% | 8.48% |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
산업 부문과의 비교: 제약, 생명공학 및 생명과학
Vertex Pharmaceuticals Inc. | 제약, 생명공학 및 생명과학 | |
---|---|---|
2023. 12. 31. | 36.68% | 16.36% |
2022. 12. 31. | 37.20% | 23.12% |
2021. 12. 31. | 30.92% | 24.90% |
2020. 12. 31. | 43.70% | 13.44% |
2019. 12. 31. | 28.27% | 23.02% |
2018. 12. 31. | 68.80% | 19.29% |
2017. 12. 31. | 10.59% | 13.08% |
2016. 12. 31. | -6.58% | 20.92% |
2015. 12. 31. | -53.89% | 21.42% |
2014. 12. 31. | -127.25% | 21.52% |
2013. 12. 31. | -36.72% | 22.24% |
2012. 12. 31. | -7.01% | 18.66% |
2011. 12. 31. | 2.10% | 15.76% |
2010. 12. 31. | -526.35% | 15.46% |
2009. 12. 31. | -630.27% | 26.03% |
2008. 12. 31. | -262.02% | 18.39% |
2007. 12. 31. | -196.61% | 16.10% |
2006. 12. 31. | -95.63% | 22.37% |
2005. 12. 31. | -126.43% | 18.45% |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
업계와의 비교: 의료
Vertex Pharmaceuticals Inc. | 의료 | |
---|---|---|
2023. 12. 31. | 36.68% | 7.65% |
2022. 12. 31. | 37.20% | 10.55% |
2021. 12. 31. | 30.92% | 11.48% |
2020. 12. 31. | 43.70% | 7.64% |
2019. 12. 31. | 28.27% | 10.09% |
2018. 12. 31. | 68.80% | 9.13% |
2017. 12. 31. | 10.59% | 7.75% |
2016. 12. 31. | -6.58% | 9.91% |
2015. 12. 31. | -53.89% | 10.98% |
2014. 12. 31. | -127.25% | 11.39% |
2013. 12. 31. | -36.72% | 11.99% |
2012. 12. 31. | -7.01% | 11.19% |
2011. 12. 31. | 2.10% | 10.02% |
2010. 12. 31. | -526.35% | 10.09% |
2009. 12. 31. | -630.27% | 14.33% |
2008. 12. 31. | -262.02% | 10.62% |
2007. 12. 31. | -196.61% | 10.58% |
2006. 12. 31. | -95.63% | 13.20% |
2005. 12. 31. | -126.43% | 12.89% |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).